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| INTRODUCTION
Sugars have emerged as the dominant nutrient of concern in the epidemics of obesity and diabetes. The fructose moiety in particular has been implicated as a potent driver of type 2 diabetes due to its unique set of biochemical, metabolic and endocrine responses. 1, 2 A less appreciated body of research suggests that small doses (≤ 10 g/meal) of fructose, at a level obtainable from fruit, may elicit a catalytic effect on hepatic glucose metabolism by increasing glycogen synthesis, as shown by 13 C nuclear magnetic resonance (NMR) under euglycaemic conditions in people without diabetes 3 and decreasing hepatic glucose output under hyperglycaemic clamp conditions in people with type 2 diabetes. 4 Clinical translation of these findings has shown that small doses of fructose decrease the postprandial blood glucose response to oral glucose in people with 5 and without type 2 diabetes. 6 Under chronic feeding conditions, fructose, in exchange for other carbohydrates, has further been shown to decrease HbA1c in systematic reviews and meta-analyses of controlled feeding trials. 7, 8 This apparent benefit, however, is tempered by evidence that fructose providing excess calories has an adverse effect on body weight, 9 fasting blood glucose levels and insulin sensitivity, 8 fasting 10, 11 and postprandial 12 triglycerides, uric acid, 13 and markers of non-alcoholic fatty liver disease (NAFLD).
14 Identifying low-calorie alternatives to fructose that share its advantages without its adverse effects is of interest. Allulose is a low-calorie (<0.2 kcal/g) C-3 epimer of fructose found naturally in small amounts in dried fruits, brown sugar and maple syrup that shares many of its functional and sensory properties and is generally regarded as safe (GRAS) as a sugar substitute by the Food and Drug Administration (FDA). [15] [16] [17] [18] It has shown similar catalytic effects on hepatic glucose metabolism in cultured hepatocytes 19, 20 and animal models. 21, 22 Small doses of allulose have also been shown to reduce the postprandial blood glucose response to high glycaemic index carbohydrate meals in people who are otherwise healthy 23 or have prediabetes. 24 Whether these effects of allulose are reproducible and are equivalent to those of fructose in people with type 2 diabetes is untested. The minimum dose at which improvements in glucose metabolism are observed also remains to be determined for both fructose and allulose in people with type 2 diabetes. 
| Trial design
The trial followed a double-blind, randomized, controlled, acute feeding, equivalence design with a ≥ 1-week washout period. Sequence randomization of the six treatments was performed using a random sequence generator. 25 The study statistician who performed this randomization was blinded to the identity of participants and did not have contact with the participants or the data. There were two levels of allocation concealment. First, the manufacturer of the treatments (Tate & Lyle Ingredients Americas LLC, Hoffman Estates, Illinois) provided unique codes for each of the six treatments. Second, the statistician who was blinded to the identity of these codes used the codes to label the packaging of the six treatments so that the treatments were only distinguishable by the participant number and the visit number to which they corresponded based on the randomization. The participants, study staff, investigators and outcome assessors were blinded to the identity of these treatment sequences. The two sets of blinding codes for each participant were not broken until all participants had completed the study and all analyses were completed.
| Treatments
Participants received a total of six treatment drinks (provided and manufactured by Tate & Lyle Ingredients Americas LLC, Hoffman
Estates, Illinois) in random order: two control drinks and four test drinks. Treatments consisted of fructose or allulose at 0 g (control), 5 g or 10 g added to a 75-g glucose solution dissolved in 500 mL of water. The drinks were matched for appearance, sweetness, texture and packaging. Flavour and colour enhancements were used to mask any differences. 
| Protocol

| Outcome measures
The pre-specified primary outcome measure was the incremental area under the curve (iAUC) for plasma glucose. Pre-specified secondary outcome measures included plasma insulin iAUC, plasma glucose and insulin absolute maximum concentrations (C max ), time of maximum concentrations (T max ), and mean incremental concentrations; the Matsuda whole body insulin sensitivity index (Matsuda ISI OGTT ); and the early insulin secretion index (ΔPI 30-0 /ΔPG 30-0 ). Exploratory outcome measures which were not pre-specified included plasma glucose and insulin total AUC, incremental C max , and mean absolute concentrations; and the insulin secretion-sensitivity index-2 (ISSI-2). 33 It was calculated using the 75-g OGTT PG and PI concentrations as follows:
| Plasma glucose and insulin analyses
where PG was expressed in mg/dL (1/18 mmol/L) and PI in μU/mL (6 pmol/L). ISSI-2 is an OGTT-derived measure of β-cell function that has been validated against the disposition index from the frequently sampled intravenous glucose tolerance. 34 It was calculated by taking the product of (1) insulin secretion as measured by the ratio of the total area-under-the-insulin-curve (AUC ins ) to the total area-underthe-glucose curve (AUC glu ), and (2) 
| Statistical analysis
Statistical analyses were performed using STATA 13.1 (StataCorp LP, College Station, Texas). Based on a 20% attrition rate, 25 participants were needed to achieve a final sample size of n = 20 to detect a difference in iAUC plasma glucose of 160 mmol × min/L (based on a 20% reduction from 800 mmol × min/L) assuming a standard deviation of 130 mmol × min/L with 90% power (1-β = 90%). 35 The sample size also provided 80% power (1-β = 80%) to detect equivalence in the iAUC plasma glucose differences between fructose and allulose using margins of AE20% assuming a standard deviation of 16.25%
(130/800 mmol × min/L*100%). 36 The 20% difference and equivalence margins were based on the minimally important difference proposed by Health Canada to support postprandial blood glucose response reduction claims. 36 Participants were excluded from analysis if fasting plasma glucose values at one or more study visits fell outside of the pre-specified tolerance limit of AE2 mmol/L of the baseline fasting plasma glucose value (defined as the mean of all six study visits).
Separate analyses were conducted for fructose and allulose with the data averaged for the two controls (0 g) for comparisons with the two other doses (5, 10 g). Linear mixed-effects models were used to assess differences in all outcome measures with unstructured covariance for repeated measures within subjects. Although it had been prespecified to use repeated measures of ANOVA with the Dunnett's test to adjust for the pairwise comparisons between each dose (5, 10 g) and the mean of the two controls (0 g) for fructose and allulose, linear mixed-effects models were selected because they allowed for the handling of missing data, fitting of the correlation between repeated measures in the same subject, and modelling of time, sequence, and carryover effects. 37, 38 The interactive effects of treatment and time (0, 30, 60, 90 and 120 minutes) on mean incremental changes in plasma glucose and insulin were assessed. Significant interactions were explored at individual time points. Linear dose-response relationships were assessed using a continuous exposure variable in the mixed-effects model, while departures from linearity were assessed by comparing the linear dose model with the categorical dose model using a likelihood ratio test. Equivalence testing was conducted using the two one-sided test (TOST) procedure by determining whether the upper and lower bounds of the 90% CI for the effect of allulose on iAUC for plasma glucose fell within the equivalence margins (AE δ) set at AE20%. 36 An equivalence test was chosen instead of a traditional comparative test to allow assessment of whether any differences between allulose and fructose were not just statistically significant but clinically significant based on the minimally important difference set by Health Canada to support postprandial blood glucose response reduction claims. 36 Subgroup analyses were conducted using linear mixed-effects models with interaction terms. Significance for the primary outcome measure was established at P < .05. To reduce the false discovery rate, secondary and exploratory outcome measures were evaluated at P < .0125. This alpha level was chosen by dividing α = 0.05/4 to adjust for the multiplicity of testing across the four broad domains of secondary and exploratory outcomes (glucose response, insulin response, insulin resistance and insulin secretion)
within which results would be expected to be correlated. All data are presented as mean AE standard error of the mean (SEM), unless specified otherwise.
3 | RESULTS
| Flow of study participants
Figure S1 (see the supporting information for this article) shows the flow of study participants. Two hundred and thirty-eight participants
were assessed for eligibility, of whom 27 were randomized. Of these, 24 participants were included in the final analysis as two participants were unable to complete the trial due to work conflicts, and one participant was excluded from analysis due to fasting plasma glucose values at one or more study visits exceeding AE2 mmol/L of their average value from all six study visits. 
| Participants' characteristics
| Secondary and exploratory outcome measures
Figures 2A and S5-7 and Table S1 show the effect of fructose at 0 g AUC (1607.7 AE 59.3 vs. 1694.1 AE 57.8 mmol × min/L) at 10 g compared with 0 g (control) (P < .0125). A significant linear dose response gradient was shown for plasma glucose absolute (P < .0001) and incremental (P < .0001) C max , total AUC (P = 0.002) and absolute mean (P = 0.001). No significant non-linear dose thresholds were identified (P > .0125). , these reductions were within the pre-specified equivalence margins of AE20%.
| Equivalence assessment
| Subgroup analyses
Figures S11 and S12 show the subgroup analyses of the pooled effect of fructose and allulose, respectively, on plasma glucose iAUC compared to control (0 g). Self-reported ethnicity was a significant effect modifier of the effect of fructose (P = 0.02), and baseline 2 h-plasma glucose (2hPG) during the 75-g OGTT (P = 0.02) and type of background diabetes therapy (P = 0.03) were significant effect modifiers of the effect of allulose.
| Side effects
Most participants tolerated the treatments well. There was one report of nausea and one report of a slight headache following consumption of the 75-g OGTT + 10 g fructose, which subsided by the end of the study visit. 
| Findings in the context of previous literature
The presence of a catalytic effect with fructose in decreasing the postprandial blood glucose response to a glucose load was not shown.
It was previously shown that 7.5 g fructose significantly reduced the 3-h plasma glucose iAUC response to a 75-g oral glucose load by 14% in individuals with type 2 diabetes. 1, 80.6 AE 11.9 and 74.1 AE 8.7, respectively (P > .05, linear mixed-effects models). *Represents a statistically significant difference (P < .0125, linear mixed-effects models) compared with control (0 g). p-values correspond to log-transformed data due to non-normal distribution of residuals. Data reported as mean AE SEM respectively, to a 75-g maltodextrin challenge. 23 In a separate study, when 11 healthy participants consumed 5 g allulose-sweetened tea with a standard meal load, no significant differences were found in postprandial glucose and insulin responses when compared to consumption of the same meal load with 10 mg aspartame-sweetened tea. 24 However, in the same study, when 15 participants with prediabetes were analysed, 5 g allulose-sweetened tea resulted in~14% reduction in postprandial blood glucose response to the standard meal load compared with aspartame-sweetened tea.
| Potential mechanism of action
The mechanism by which allulose reduces the postprandial blood glucose response to an oral glucose load is unclear. One possibility is enhanced glucose-stimulated insulin secretion by allulose. This mechanism was not supported by the trial's data as allulose failed to show a significant effect on plasma insulin iAUC responses, the insulin secretion index (ΔPI 30-0 /ΔPG 30-0 ), or the ISSI-2.
Another possibility is reduced intestinal absorption of glucose in the presence of allulose. Glucose and allulose pass through different transporters (SGLT1 and GLUT2, respectively) as they move from the intestinal lumen to the apical membrane of the enterocyte. However, they utilize the same transporter (GLUT2) as they pass from the basolateral membrane of the enterocyte to the portal circulation. 40 It has been suggested that allulose may competitively inhibit the transport of glucose at the basolateral GLUT2 transporter. Support for this hypothesis is provided from experiments conducted in Caco-2 monolayer cell lines where the addition of 30 mM allulose to 30 mM glucose reduced glucose permeability by 60%. 41 No studies have been conducted in humans to confirm this mechanism.
There has also been some suggestion that allulose may reduce where it can drive hepatic glucose uptake, promote glycogen synthesis, suppress hepatic glucose output and reduce plasma glucose levels. 40 In support of this hypothesis, immunohistochemical analyses in allulose-fed rats have shown induction of glucokinase translocation from the nucleus to the cytoplasm and an increased amount of hepatic glycogen content after glucose loading. 22, 44 No studies have been conducted in humans to confirm this mechanism.
| Implications
The implications of these findings are that allulose may be a useful substitute for sugars, especially when consumed as part of high glycaemic index carbohydrate foods. Allulose tastes~70% as sweet as sucrose and contains 90% fewer calories. When consumed alone, allulose does not raise blood glucose and insulin levels in healthy individuals. 23 The current study, along with a previous study in participants with prediabetes, has shown that the addition of small doses of allulose also helps to lower the postprandial blood glucose response to high glycaemic index carbohydrate meals (i.e. 75-g OGTT or standard
Japanese meal) by~8% to 14%. 24 This decrease is modest when compared to an oral antihyperglycaemic agent such as acarbose, which has shown reductions of~31% to 58% on postprandial glycaemia when administered with a meal load.
45,46
| Strengths and limitations
This acute trial had several strengths. These included the randomized double-blind controlled design, which provides the best protection against bias; a crossover design, which allows each participant to act as their own control thus reducing between-subject variation; a 3 Equivalence assessment comparing the effect of allulose with fructose on plasma glucose incremental area under the curve (iAUC); % difference plasma glucose iAUC = [(allulose iAUCglucose /control iAUCglucose ) -(fructose iAUCglucose /control iAUCglucose )] × 100%. Equivalence margins (+δ, −δ) were set at −20%, +20%. If the 90% CIs completely fell within the equivalence margins, then allulose was considered equivalent to fructose. If either the upper or lower bound of the 90% CI fell outside the equivalence margins, then the assessment was considered inconclusive. If the 90% CIs fell either completely above or completely below the equivalence margins, then allulose was considered inferior or superior to fructose, respectively reliable estimate of fasting glucose and insulin based on the mean of two fasting samples at −30 and 0 minutes; and a reliable estimate of the comparator based on the mean of two separate controls (0 g). This acute trial also had several limitations. First, the 2 hours duration of the OGTTs may not have been long enough to detect meaningful differences in postprandial glucose and insulin responses, as individuals with type 2 diabetes typically return to baseline after 3 hours or longer. [47] [48] [49] Second, the trial was not designed to examine the mechanism(s) by which allulose reduced the postprandial blood glucose response to an oral glucose load. Third, although a significant linear dose response for allulose was found, the doses examined may have been too few or insufficient to detect dose-response gradients or thresholds. Finally, the acute design of the trial creates uncertainty as to whether the reductions in the postprandial blood glucose response seen with allulose will manifest as sustainable improvements in glycaemic control (i.e. HbA1c) over the long term.
In conclusion, it was shown that allulose, but not fructose, mod- 
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